Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis

British Journal of Rheumatology

Volumn 37, Issue 1, 1998, Pages 34-38

  Ronday, H K ^a,b   Te Koppele, J M ^a   Greenwald, R A ^d   Moak, S A ^d   De Roos, J A D M ^a   Dijkmans, B A C ^a,c   Breedveld, F C ^b   Verheijen, J H ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Collagen cross links; Plasminogen activation system; Tranexamic acid

Indexed keywords

COLLAGEN; DEOXYPYRIDINOLINE; PLASMINOGEN; PYRIDINOLINE; TRANEXAMIC ACID;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JOINT DESTRUCTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; URINARY EXCRETION;

EID: 0031877504     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/37.1.34     Document Type: Article

References (23)

1. Hamilton JA. Plasminogen activator activity of rheumatoid and nonrheumatoid synovial fibroblasts. J Rheumatol 1982;9:834-42.
2. Inman RD, Harpel PC. Alpha2-plasmin inhibitor-plasmin complexes in synovial fluid. J Rheumatol 1986;13:535-7.
3. Kikuchi H, Tanaka S, Matsuo O. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1987;14:439-45.
4. Quax PHA, van Muijen GNP, Pedersen N et al. The plasminogen activator system in extracellular matrix degradation. Fibronolysis 1992;6(suppl. 4):41-4.
5. Werb Z, Mainardi C, Vater CA, Harris ED. Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977;296:1017-23.
6. Ronday HK, Smits HH, van Muijen GNP et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996;35:416-23.
7. Ronday HK, Smits HH, Quax PHA et al. Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. Br J Rheumatol 1997;36:9-15.
8. Andersson L, Nilsson IM, Niléhn J-E et al. Experimental and clinical studies on AMCA, the anti-fibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol 1965;2:230-47.
9. Ahlberg Å, Eriksson O, Kjellman H et al. Diffusion of tranexamic acid to the joint. Acta Orthoped Scand 1977;47:486-8.
10. Pilbrant A, Schannong M, Wessmann J. Pharmakinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol 1981;20:65-72.
11. Ogston D. Mechanism of action of anti-fibrinolytic agents. Anti-fibrinolytic drugs John Wiley and Sons, Chichester, 1984.
12. Seibel MJ, Duncan A, Robins SP. Urinary hydroxy pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic disease. J Rheumatol 1989;16:964-70.
13. Gough AKS, Peel NFA, Eastell R, Holder RL, Lilley J, Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994;53:14-17.
14. Black D, Marabani M, Sturrock RD, Robins SP. Urinary excretion of hydroxy pyridinium crosslinks of collagen in patients with rheumatoid arthritis. Ann Rheum Dis 1959;48:641-4.
15. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Prevoo MLL, Van't Hoff MA, Kuper HH, Van Leeuwen MA, Van de Putte LBA, Van Riel PLCM. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
17. Butler M, Colombo C, Hickman L et al. A new model of osteoarthritis in rabbits. Evaluation of anti-osteoarthritis effects of selected drugs administered intraarticularly. Arthritis Rheum 1983;26:1380-6.
18. Vignon E, Mathieu P, Bejui J et al. Study of an inhibitor of plasminogen activator (tranexamic acid) in the treatment of experimental osteoarthritis. J Rheumatol 1991;18(suppl. 27):131-3.
19. Kummer JA, Abbink JJ, De Boer JP et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum 1992;35:884-93.
20. Medcalf RL, Hamilton JA. Human synovial fibroblasts produce urokinase-type plasminogen activator. Arthritis Rheum 1986;29:1397-401.
21. Gonzalez-Gronow M, Gawdi G, Pizzo SV. Characterization of the plasminogen receptor of normal and rheumatoid arthritis human synovial fibroblasts. J Biol Chem 1994;269:4360-6.
22. Quax PHA, Pedersen N, Masucci MT et al. Complementation between urokinase producing and receptor producing cells in extracellular matrix degradation. Cell Regul 1991;2:793-803.
23. Zvaifler NJ, Firestein GS. Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994;37:783-9.